Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(03): 159-163
DOI: 10.4103/0971-5851.123712
ORIGINAL ARTICLE

Report of chronic myeloid leukemia from All India Institute of Medical Sciences, 1990-2010

Pravas Mishra
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
,
Tulika Seth
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
,
Sudha Sazawal
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
,
Manoranjan Mahapatra
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
,
Renu Saxena
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

All India Institute of Medical Sciences, New Delhi is an Apex Institute and caters to more than 1.5 million out-patients and 80,000 in-patients every year. In this study, we have presented data of patients over a period of 20 years. This encompasses our initial experience with hydroxyurea, then interferon alone or with cytarabine and finally imatinib. We have presented data of 525 patients treated on imatinib alone. Imatinib dose was increased in 56 (10.6%) patients and regain of complete hematological response was seen in 26 patients. A total of 14 patients were transplanted for different indications of chronic myeloid leukemia and out of which 12 patients are doing well, while two died due to Grade IV gut graft-versus-host disease.

Keywords

Chronic myeloid leukemia - All India Institute of Medical Sciences - Imatinib


Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hasan SK, Sazawal S, Kumar B, Chaubey R, Mishra P, Mir R, et al. Childhood CML in India: b2a2 transcript is more common than b3a2. Cancer Genet Cytogenet. 2006;169:76-7.
  • 2 Mishra P, Mahapatra M, Kumar R, Dixit A, Chatterjee T, Tyagi S, et al. Philadelphia-chromosome positive thrombocythemia in a child. Eur J Haematol. 2005;75:262-3.
  • 3 Dolai TK, Bhargava R, Mahapatra M, Mishra P, Seth T, Pati HP, et al. Is imatinib safe during pregnancy? Leuk Res. 2009;33:572-3. Epub 2008.
  • 4 Choudhary DR, Mishra P, Kumar R, Mahapatra M, Choudhry VP. Pregnancy on imatinib: Fatal outcome with meningocele. Ann Oncol. 2006;17:178-9. Epub 2005 Nov 15.
  • 5 Mahapatra M, Mishra P, Kumar R. Imatinib-induced Stevens-Johnson syndrome: Recurrence after re-challenge with a lower dose. Ann Hematol. 2007;86:537-8.
  • 6 Bhargav R, Mahapatra M, Mishra P, Kumar R. overdose with 6400 mg of imatinib. Ann Oncol. 2007;18:1750-1751.
  • 7 Sazawal S, Hasan SK, Kumar B, Kumar R, Kumar L, Saxena R. Timing of allogeneic BMT for CML patients in India: Does it affect response? Am J Hematol. 2007;82:329.